Molecular Therapy - Methods & Clinical Development

Slides:



Advertisements
Similar presentations
Molecular Therapy - Methods & Clinical Development
Advertisements

Molecular Therapy - Methods & Clinical Development
Volume 3, Issue 5, Pages (May 2001)
Volume 8, Issue 2, Pages (August 2003)
Molecular Therapy - Methods & Clinical Development
Volume 22, Issue 2, Pages (February 2014)
Jennifer R. Hamilton, Gayathri Vijayakumar, Peter Palese  Cell Reports 
Molecular Therapy - Methods & Clinical Development
Deletion of the Virion Host Shut-off Gene Enhances Neuronal-Selective Transgene Expression from an HSV Vector Lacking Functional IE Genes  Yoshitaka Miyagawa,
Volume 16, Issue 1, Pages (January 2008)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Oncolytics
Volume 10, Issue 1, Pages (July 2004)
Volume 15, Issue 4, Pages (April 2014)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Methods & Clinical Development
Vaccinia virus as a subhelper for AAV replication and packaging
Volume 24, Issue 5, Pages (May 2016)
Volume 23, Issue 10, Pages (October 2015)
Molecular Therapy - Methods & Clinical Development
High-accuracy biodistribution analysis of adeno-associated virus variants by double barcode sequencing  Damien Marsic, Héctor R Méndez-Gómez, Sergei Zolotukhin 
Generation of a Flexible Cell Line with Regulatable, High-Level Expression of HIV Gag/Pol Particles Capable of Packaging HIV-Derived Vectors  Sandra Sparacio,
Hemagglutinin-targeting Artificial MicroRNAs Expressed by Adenovirus Protect Mice From Different Clades of H5N1 Infection  Xinying Tang, Hongbo Zhang,
Volume 7, Issue 1, Pages (January 2003)
Molecular Therapy - Methods & Clinical Development
Targeting Dyrk1A with AAVshRNA Attenuates Motor Alterations in TgDyrk1A, a Mouse Model of Down Syndrome  Jon Ortiz-Abalia, Ignasi Sahún, Xavier Altafaj,
Volume 3, Issue 4, Pages (April 2001)
Molecular Therapy - Oncolytics
Volume 22, Issue 1, Pages (January 2014)
Incorporation of the B18R Gene of Vaccinia Virus Into an Oncolytic Herpes Simplex Virus Improves Antitumor Activity  Xinping Fu, Armando Rivera, Lihua.
Keratinocyte growth factor promotes goblet cell differentiation through regulation of goblet cell silencer inhibitor  Dai Iwakiri, Daniel K. Podolsky 
Generation of a stable packaging cell line producing high-titer PPT-deleted integration- deficient lentiviral vectors  Peirong Hu, Yedda Li, Mark S Sands,
Volume 8, Issue 4, Pages (October 2003)
Richard A Voit, Moira A McMahon, Sara L Sawyer, Matthew H Porteus 
Volume 23, Issue 4, Pages (April 2015)
Volume 23, Issue 4, Pages (April 2015)
Volume 12, Issue 5, Pages (November 2005)
Volume 16, Issue 6, Pages (June 2008)
Volume 12, Issue 5, Pages (November 2005)
Herpesvirus-Mediated Systemic Delivery of Nerve Growth Factor
Volume 22, Issue 1, Pages (January 2014)
Attenuated Cold Sensitivity in TRPM8 Null Mice
Poxviral B1 Kinase Overcomes Barrier to Autointegration Factor, a Host Defense against Virus Replication  Matthew S. Wiebe, Paula Traktman  Cell Host.
Assessing the Functional Characteristics of Synonymous and Nonsynonymous Mutation Candidates by Use of Large DNA Constructs  A.M. Eeds, D. Mortlock, R.
Volume 8, Issue 2, Pages (August 2003)
Volume 18, Issue 5, Pages (May 2010)
Molecular Therapy - Methods & Clinical Development
Volume 6, Issue 3, Pages (September 2002)
Volume 56, Issue 5, Pages (November 1999)
Kasey L Jackson, Robert D Dayton, Ronald L Klein 
Rodney P. DeKoter, Hyun-Jun Lee, Harinder Singh  Immunity 
Effect of Genome Size on AAV Vector Packaging
Cheryl A. Carlson, Dmitry M. Shayakhmetov, André Lieber 
Volume 6, Issue 4, Pages (October 2007)
Jiamiao Lu, Feijie Zhang, Mark A Kay  Molecular Therapy 
Volume 19, Issue 3, Pages (March 2011)
Volume 4, Issue 4, Pages (October 1999)
Fetal Brain-directed AAV Gene Therapy Results in Rapid, Robust, and Persistent Transduction of Mouse Choroid Plexus Epithelia  Marie Reine Haddad, Anthony.
Volume 15, Issue 4, Pages (April 2014)
Volume 20, Issue 2, Pages (August 2016)
Volume 122, Issue 3, Pages (August 2005)
Deletion of the Virion Host Shut-off Gene Enhances Neuronal-Selective Transgene Expression from an HSV Vector Lacking Functional IE Genes  Yoshitaka Miyagawa,
Tumor Growth Inhibition by Intratumoral Inoculation of Defective Herpes Simplex Virus Vectors Expressing Granulocyte–Macrophage Colony-Stimulating Factor 
Volume 10, Issue 1, Pages (July 2004)
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Methods & Clinical Development
Presentation transcript:

Molecular Therapy - Methods & Clinical Development An HSV-based library screen identifies PP1α as a negative TRPV1 regulator with analgesic activity in models of pain  Bonnie Reinhart, William F Goins, Asaff Harel, Suchita Chaudhry, James R Goss, Naoki Yoshimura, William C de Groat, Justus B Cohen, Joseph C Glorioso  Molecular Therapy - Methods & Clinical Development  Volume 3, (January 2016) DOI: 10.1038/mtm.2016.40 Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 Transient receptor potential vanilloid 1 (TRPV1) vector and antagonist screen designs. (a) KOS-37 bacterial artificial chromosome (BAC) genome representation (top) with the locations of relevant genomic regions indicated. TRL, TRS, terminal repeats of the unique long (UL) and unique short (US) segment, respectively; IRL, IRS, internal repeats; BAC, loxP-flanked BAC sequences; UL23, tk gene; UL41, vhs gene. The TTA BAC genome represented underneath contained a CMV promoter–driven Gateway (GW) cassette replacing IRL and IRS (ΔJ); TRPV1 (VR1) cDNAs expressed from the early (β) tk promoter in place of (Δ) UL23 and UL41; and an ampicillin resistance gene (AmpR) between UL55 and UL56. (b) Western blots of infected cell lysates. Vero cells were infected with the vT-GFP vector (MOI = 3) and processed at the indicated time points for immunoblotting with antibodies to TRPV1, GFP, or β-actin. (c) Generation of TTA BAC and viral libraries. The range of cDNA sizes recombined into TTA BAC was estimated by polymerase chain reaction with flanking primers and gel electrophoresis of the products (Library). TTA BAC DNA was used as control (TTA). (d) Summary of the library screen. Molecular Therapy - Methods & Clinical Development 2016 3, DOI: (10.1038/mtm.2016.40) Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 Herpes simplex virus vector-mediated protein phosphatase 1α (PP1α) or poreless (PL) expression in vitro and in vivo reduces transient receptor potential vanilloid 1 (TRPV1) channel activity. (a) Growth of vTTA, vTTA-PP1α, and vTTA-PL viruses on capsaicin-treated or untreated Vero cells. Cells were infected at an MOI of 0.01 and virus yields were determined at 48 hpi. Bars represent the mean ± SD of duplicate experiments; no virus was detected in TTA virus-infected, capsaicin-treated cells. (b) Effect of virus-mediated PP1α expression on calcium influx in response to capsaicin. Neurons isolated from DRGs of fetal rats were infected with DBAC-PP1α, DBAC-PL, or DBAC-GFP, and the increase in intracellular calcium (mean increase ± SD in the F340/F380 ratio) after capsaicin treatment is shown (*P < 0.001; Student's t-test). (c–e) Male Sprague-Dawley rats were injected subcutaneously into the right hind paw with 1 × 108 pfu of DBAC-GFP, DBAC-PP1α, or DBAC-PL virus. (c) Thermal latency responses were measured using a Hargreaves apparatus and plotted for each group as the mean ± SD of the response times (in seconds) for uninjected left (white) and injected right (black) hind paws. (*P < 0.001, **P < 0.0001). (d–e) Thermal allodynia was assessed using a dynamic hot plate in the (d) absence or (e) presence of capsaicin, and the results were plotted as the mean ± SD of the number of responses by each animal per group. Student's t-test was used to compare the control DBAC-GFP group with DBAC-PL and DBAC-PP1α (*P < 0.05 and **P < 0.01). BAC, bacterial artificial chromosome. Molecular Therapy - Methods & Clinical Development 2016 3, DOI: (10.1038/mtm.2016.40) Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 3 Herpes simplex virus vector-mediated PP1α or poreless (PL) expression did not significantly alter cold- or formalin-induced pain responses. Male Sprague-Dawley rats injected subcutaneously into the right rear hindpaw with DBAC-GFP, DBAC-PP1α, or DBAC-PL virus (n = 4/group). (a) Animals were placed on a dynamic cold plate where temperature decreased from 20 to 4°C over a 15-minute period. The total number of pain-related behaviors (licking, paw withdrawals) observed for the injected paw during each degree interval are plotted as the mean ± SD. (b) The injected paws were treated with icilin, and cold allodynia was assessed as in a. (c) The injected paws were treated with menthol, and responses were assessed as in a. (d) Quantitation of nocifensive behavior in the formalin footpad test. A weighted pain score was plotted against time and compared between control and treatment groups using one-way analysis of variance. No significant differences were noted between the PP1α, PL, and GFP vector-injected animals in any of the above assays. BAC, bacterial artificial chromosome. Molecular Therapy - Methods & Clinical Development 2016 3, DOI: (10.1038/mtm.2016.40) Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions